Proton Therapy and Concomitant Capecitabine for Non-Metastatic Unresectable Pancreatic Adenocarcinoma
|
|
- Magdalene Sherilyn Owens
- 5 years ago
- Views:
Transcription
1 Proton Therapy and Concomitant Capecitabine for Non-Metastatic Unresectable Pancreatic Adenocarcinoma Suzanne Sachsman, MD 1 ; R. Charles Nichols, Jr, MD 1 ; Christopher G. Morris, MS 1 ; Robert Zaiden, MD 1 ; Elizabeth A. Johnson, MD 2 ; Ziad Awad, MD 3 ; Debashish Bose, MD 4 ; Meng Wei Ho, MSc 1 ; Soon N. Huh, MD 1 ; Zuofeng Li, DSc 1 ; Patrick Kelly, MD 4 ; Bradford S. Hoppe, MD 1 1 University of Florida Proton Therapy Institute, Jacksonville, FL, USA 2 Mayo Clinic Jacksonville, Jacksonville, FL, USA 3 University of Florida Department of Surgery, Jacksonville, FL, USA 4 UF Health Cancer Center, Orlando Health, Orlando, FL, USA Abstract Submitted 06 May 2014 Accepted 17 Jun 2014 Published 31 Dec 2014 Corresponding author: R. Charles Nichols University of Florida Proton Therapy Institute 2015 North Jefferson St Jacksonville, FL 32206, USA Phone: þ1 (904) Fax: þ1 (904) rnichols@floridaproton.org Original Article DOI /IJPT * cc Copyright 2014 International Journal of Particle Therapy Distributed under Creative Commons CC-BY OPEN ACCESS Purpose: To review early outcomes for patients enrolled on our institution s protocol (PC01) for patients with unresectable pancreatic cancer, and to test whether the serious adverse event rate could be reduced from 15% (expected) to,5%. Patients and Methods: Twelve patients were enrolled, but only 11 patients are reported in this analysis. Pathology on all patients was reviewed at University of Florida Health Medical Center in Jacksonville to confirm the diagnosis of pancreatic adenocarcinoma. Unresectability was defined by radiographic evidence of encasement of the celiac axis and/or superior mesenteric artery or by occlusion of the superior mesenteric vein, portal vein, or both confluences. Patients received proton therapy to a planning target volume dose of 59.4 Gy (relative biological effective) at 1.8 Gy (relative biological effective) per fraction over 7 weeks with concomitant oral capecitabine (1000 mg orally twice-daily, 5 days/week on radiation treatment days only). Only gross disease was targeted. Results: Median follow-up for all patients was 14 months (range, 5 to 25 months). Median follow-up for surviving patients was 23 months (range, 8 to 25 months). Median age was 68 years (range, 51 to 86 years). One- and 2-year overall survival, progression-free survival, distant metastasis-free survival, and freedom from local progression rates were 61% and 31% (median, 18.4 months), 55% and 14%, 68% and 27%, and 86% and 69%, respectively. No patient experienced a grade 3 or greater toxicity during treatment or follow-up. Grade 2 toxicity was limited to a single patient experiencing grade 2 fatigue. Median weight loss over the course of treatment was 1.7 kg (range, loss of 5.7 to gain of 4.9 kg). Four patients had an adequate radiographic response to radiation therapy to justify surgical exploration. Conclusion: Proton therapy with concomitant capecitabine as delivered on the PC01 protocol was well-tolerated with no grade 2 or greater gastrointestinal toxicities. The 18.4-month median survival and the 69% freedom from local progression at 2 years are encouraging. The lack of meaningful gastrointestinal toxicity suggests significant How to cite this article Sachsman S, Nichols RC, Morris CG, Zaiden R, Johnson EA, Awad Z, Bose D, Ho MW, Huh SN, Li Z, Kelly P, Hoppe BS. Proton Therapy and Concomitant Capecitabine for Non-Metastatic Unresectable Pancreatic Adenocarcinoma. Int J Particle Ther. 2014;1(3):
2 opportunities for treatment intensification when proton therapy is used in this setting. Keywords: pancreas; adenocarcinoma; proton therapy; radiation therapy; chemotherapy Introduction Conventional x-ray-based radiation therapy, with or without concomitant chemotherapy, for patients with unresectable pancreatic cancer is associated with poor survival. The median survival rates for the radiation therapy arms in 5 prospectively randomized series range from 8.3 to 11.1 months [1 5]. Effective radiation therapy delivery for these patients is compromised by the fact that x- ray beams directed at the critical tumor target must often pass through the spinal cord, liver, and kidneys. Additionally, the pancreas is intimately surrounded by highly radiosensitive structures including the stomach, duodenum, and jejunum. As a result, it is difficult to deliver conventionally fractionated radiation therapy doses much in excess of 54 Gy, particularly if radiosensitizing chemotherapy is utilized. Although, historically, radiation therapy combined with chemotherapy has been offered as a standard treatment for patients with unresectable pancreatic cancer, results from a large recent randomized study was unable to identify a survival benefit for chemoradiation therapy compared to treatment with chemotherapy alone [6]. Various dosimetric studies have suggested that proton therapy, by virtue of its ability to create more conformal radiation therapy dose distributions, may be able to improve the therapeutic index for patients with pancreatic cancer when compared to treatment with x- ray-based therapies [7 10]. A prior publication from our institution including patients with unresectable cancer, marginally resectable cancer, or those treated postoperatively demonstrated low gastrointestinal toxicities for patients treated with proton therapy and concomitant oral capecitabine [11]. Herein we present the first reported outcomes for a prospective clinical trial utilizing conventionally fractionated proton beam radiation therapy with concomitant chemotherapy for patients with unresectable pancreatic cancer. Patients and Methods The University of Florida Proton Therapy Institute PC01 protocol received initial institutional review board approval on July 27, The first patient was enrolled in April The accrual target was 66 patients to test if the expected serious adverse event rate could be reduced from the expected 15% to, 5%. Unresectability was defined by radiographic evidence of encasement of the celiac axis, the superior mesenteric artery, or both or by occlusion of the superior mesenteric vein, portal vein, or both confluences. Protocol therapy consisted of proton therapy to a planning target volume dose of 59.4 Gy (relative biological effective [RBE]) at 1.8 Gy (RBE) per fraction over 7 weeks with concomitant oral capecitabine (1000 mg orally twice daily, 5 days per week on radiation treatment days only). Only gross disease was targeted. Technical Aspects of Treatment Delivery All patients underwent a 4-dimensional computed tomography scan with intravenous and oral contrast for treatment planning. Although the protocol allowed for the use of fiducial markers, in practice, they were not utilized for patient positioning during treatment. An Sachsman et al. (2014), Int J Particle Ther 693
3 internal gross tumor volume (IGTV) was established for all patients. A clinical target volume was created by expanding the IGTV by between 3 and 10 mm. A planning target volume was established for all patients providing a margin between 5 and 10 mm around each clinical target volume to compensate for the variability of treatment setup and internal motion. In summary, the minimum expansion on the IGTV was 8 mm and the maximal expansion was 20 mm. Weekly verification scans were performed on all patients during treatment to assess target motion and, as necessary, allow for adaptive replanning over the course of proton therapy. Critical normal structures at risk of toxicity were contoured, including the right and left kidneys, liver, small bowel, and spinal cord. Nuclear medicine renal scans were performed on all patients to assess the bilaterality of renal function. Normal-tissue constraints were established to assure that at least two-thirds of the volume of one functioning kidney received a dose of less than 20 Gy (RBE). The hepatic V30 Gy (RBE) was limited to 50% and the V35 Gy (RBE) was limited to 33% of the liver volume. The small intestine volume was established as a small bowel space. Individual loops of bowel were not contoured. Protocol guidelines indicated that no more than 10% of the total small intestine or gastric volumes should receive greater than 50 Gy (RBE) and that no more than 15% of the volume should receive greater than 45 Gy (RBE). Duodenal mean dose was suggested to be, 50 Gy (RBE). In practice, a retrospective review indicated that the entire duodenum in most patients receive the entire prescription dose. Maximum spinal cord dose was limited to 45 Gy (RBE) to 0.1 cm 3. Passive double-scattering proton beams were used to deliver the proton therapy treatments, utilizing apertures and range compensators for lateral and distal dose distribution conformity, respectively. While the double-scattering technique is unable to provide dose conformity in the entrance region to the treatment target, the rapid formation of the spread-out Bragg peaks from our proton therapy system (IBA, Louvain la Neuve, Belgium), at a frequency of 10 Hz, renders the dose delivery insensitive to organ motion, particularly with moving targets such as the pancreas. All patients were treated utilizing a 2-field technique consisting of a heavily weighted posterior-anterior field combined with a single right lateral or right lateral oblique field. For most patients, 75% of the dose was delivered through the posterior field while respecting the constraints on the spinal cord dose, which was limited to 45 Gy (RBE) as described above. The remainder of the dose was delivered through the right lateral field. Anterior and left lateral fields were avoided to minimize small bowel and gastric exposure. The choice to use a posterior-anterior field that penetrates the patient s spine before reaching the target maximizes the robustness of the delivered dose distribution due to the minimal daily anatomical variations that may perturb the delivered beam ranges. Range uncertainties for the lateral treatment field, which typically passes through the liver, could be caused by liver motion and the daily variations of small bowel contents. Robustness of the lateral treatment field was carefully evaluated by calculating the verification treatment plans with the bowel contents overridden alternatively with air or water for the planned dose distribution to meet the planning goals when either air or water was present in the small bowels. A typical plan is shown in Figure 1. Chemotherapy consisted of capecitabine at a fixed dose of 1000 mg orally twice a day on days when radiation therapy was delivered. Patients were asked to maintain a pill diary documenting self-administration of the drug. The diary was reviewed with nursing on a weekly basis. Standard chemotherapy dose modification guidelines were utilized although there were no protocol patients who were unable to receive chemotherapy. Sachsman et al. (2014), Int J Particle Ther 694
4 Figure 1. (A) The typical proton therapy plan utilizing 3:1 posterior-anterior-oblique : right-left (PAO:RL) weighting; (B) the cumulative dose histogram. Sachsman et al. (2014), Int J Particle Ther 695
5 Patients were allowed to receive chemotherapy before chemoradiation as long as the regimens did not cause hematologic toxicity that would prohibit protocol enrollment. Patients were encouraged, but not required, to receive post-chemoradiation chemotherapy consisting of gemcitabine at 1000 mg/m 2 on days 1, 8, and 15 of each 28-day cycle for a total of 4 cycles starting 4 weeks after completing proton therapy with oral capecitabine. Results Twelve patients were enrolled, but only 11 patients are reported in this analysis because 1 patient died of a gunshot wound 5 days after starting treatment. The median follow-up from the start of treatment for all patients was 14 months (range, 5 to 25 months). The median follow-up for surviving patients was 23 months (range, 8 to 25 months). The median age of enrolled patients was 68 years (range, 51 to 86 years). In total, 6 patients were female, 5 male, 2 Hispanic, and 9 white. Only 1 of the 11 patients evaluated underwent bypass surgery prior to chemoradiation. There were no interruptions in treatment for any of the patients. Treatment duration ranged from 45 to 50 calendar days. There were no interruptions in chemotherapy delivery and there were no chemotherapy-related toxicities. Seven of the 11 patients received all prescribed 66 chemotherapy doses. Two patients received 65 of the prescribed 66 doses. Two patients with insurance coverage issues received 62 of the prescribed 66 doses. Cancer antigen 19-9 levels prior to protocol treatment ranged from 13 to Eight of the 11 patients received cytotoxic chemotherapy prior to proton therapy. Five were treated with single-agent gemcitabine and 3 were treated with the folfirinox regimen. The pretreatment characteristics of the evaluable patients, including criteria for unresectability, are shown in Table 1. The 1- and 2-year overall survival rates were 61% and 31% (median, 18.4 months; Figure 2). The 1- and 2-year progression-free survival rates were 55% and 14%. The 1- and 2-year freedom from distant metastasis rates were 68% and 27%. The 1- and 2-year freedom from local progression rates were 86% and 69% (Figure 2). No patient experienced any grade 3 or greater toxicity during treatment or during the follow-up period. Grade 2 toxicity was limited to a single patient experiencing grade 2 fatigue. Median weight loss over the course of treatment was 1.7 kg (range, loss of 5.7 to gain of 4.9 kg). Four patients were deemed to have had an adequate radiographic response to radiation therapy to justify surgical exploration. Two of these patients underwent palliative R2 resections. Both are alive without evidence of local disease progression at 25 (Patient #5) and 22 (Patient #10) months after proton therapy, although the first developed an isolated liver metastasis and was treated with palliative stereotactic radiation therapy. The second patient developed diffuse intraperitoneal dissemination and is receiving chemotherapy. One patient (#6) underwent negative biopsies of the pancreatic head with distal pancreatectomy and was found to be without pathologically identifiable disease in any of the resected specimens. He is alive without disease progression at 24 months. One patient (#8) was found to have intra-abdominal metastases at surgery and the planned Whipple procedure was aborted. Discussion The long-term survival expectation for a patient diagnosed with locally advanced unresectable pancreatic adenocarcinoma, even in the absence of radiographic evidence of Sachsman et al. (2014), Int J Particle Ther 696
6 Table 1. Patient characteristics. Patient no. Gender Age (years) Stage Prior Pretreatment bypass cancer Pre-chemoradiation surgery antigen19-9 chemotherapy Criteria for unresectability 1 F 67 T4N1M0 Yes Portal vein occlusion 2 M 58 T4N0M0 No Portal vein occlusion 3 F 68 T4N0M0 No Gemcitabine Portal vein occlusion; SMV occlusion 4 M 70 T4N0M0 No Gemcitabine SMA encasement 5 M 67 T4N0M0 No Folfirinox IVC encasement; invasion of posterior abdominal wall at attempted surgery 6 M 68 T4N1M0 No Gemcitabine SMA encasement; celiac encasement 7 F 63 T4N0M0 No SMA encasement, SMV occlusion 8 F 72 T3N1M0 No Folfirinox Portal vein occlusion by nodal mass 9 F 75 T4N0M0 No Gemcitabine SMA encasement, portal vein occlusionn 10 M 51 T4N0M0 No Folfirinox SMA encasement; celiac encasement 11 M 86 T4N0M0 No Gemcitabine SMA encasement; celiac encasement Abbreviations: IVC, intravenous contrast; SMA, superior mesenteric artery; SMV, superior mesenteric vein hematogenous dissemination, remains poor. The current series is no exception with only 1 patient without evidence of disease progression at 24 months of follow-up. At the same time, the moderately high rate of local control (64% freedom from local progression at 2 years) and survival (median 18.4 months) combined with the lack of any meaningful toxicity with the regimen described herein strongly suggests the potential for treatment intensification when proton therapy is utilized in this setting. Figure 2. Overall survival and freedom from local progression at 2 years. Sachsman et al. (2014), Int J Particle Ther 697
7 Various studies in the contemporary radiation therapy literature discuss the utilization of stereotactic body radiation therapy in the treatment of patients with locally advanced, unresectable pancreatic cancers. While the local control rates for this modality are impressive, ranging from 84% to 94% at 12 months [12, 13], grade 3 gastrointestinal toxicity has been reported to be as high as 10% [14]. Importantly, while the dose/ fractionation regimens utilized in stereotactic body radiation therapy regimens may be effective and safe when small volumes are treated, it is unlikely that stereotactic body radiation therapy would have any relevance in the neoadjuvant setting where the value of radiation therapy would better be defined by its ability to sterilize microscopic nodal or peripancreatic disease at the periphery of the surgical field. In contrast, a prior publication from our institution [15] indicates that proton therapy, by virtue of the dose distributions achieved, would allow for elective nodal coverage in the neoadjuvant setting without increasing critical normal tissue exposures when compared to treatment of the gross disease alone. With regard to normal tissue toxicity, a prior study from the M.D. Anderson Cancer Center (Houston, TX) [16] suggests that the duodenum is not able to tolerate doses greater than 55 Gy. This stands in contrast to the current series where, based on retrospective analysis of dose distributions, 100% of the duodenum appeared to receive the entire prescription dose of Gy (RBE). Admittedly, 2 of the 3 patients who experienced long-term survival ultimately underwent a Whipple procedure, complicating longitudinal assessment of duodenal toxicity since their duodenums were resected. On the other hand, the absence of any suggestion of gastrointestinal toxicity in the other patients, including the 1 patient who is a long-term survivor at 2 years, raises the possibility that the duodenum may be able to tolerate higher radiation therapy doses provided other upper gastrointestinal structures (such as the jejunum and stomach) receive only minimal exposure as is the case with proton therapy. In contrast to the current series demonstrating negligible toxicity for patients with locally advanced pancreas cancer treated with protons, Takatori et al [17] reported an analysis of the upper gastrointestinal complications associated with gemcitabine concurrent proton radiation therapy for patients with inoperable pancreatic cancer. The study demonstrated a 49.4% rate of gastric/duodenal ulceration in the treated patients. Terashima had previously reported favorable local control and 1-year survival rates with this regimen [18]. Patients on this study were treated with a very aggressive radiation therapy protocol consisting of 67.5 Gy (RBE) at 2.7 Gy (RBE) per fraction with concomitant full-dose gemcitabine at 800 mg/m 2 on days 1, 8, and 15. Additionally, the radiation therapy fields covered gross disease as well as regional nodal beds. While the results of this study imply that proton radiation therapy may be excessively toxic for patients with inoperable pancreatic cancer, it appears more likely that the severe toxicity demonstrated was a function of the aggressiveness of the chemoradiation therapy regimen utilized. A letter [19] pointing out these issues has been published. Advanced immobilization techniques, such as the use of breath hold gating or targeting with implanted fiducial markers, were not used in this series. These technologies may be relevant for future studies with intensified treatment regimens. For the most part, motion studies were made on our 4-dimensional computed tomography scans prior to treatment delivery. The motion identified was virtually always in the range of less than 8 mm, which was well within our established planned target volume expansion beyond the IGTV. As such, it was argued that the use of breath hold or fiducial markers was unnecessary. An additional concern with shifting the patient based on fiducial marker location was the possibility that such a shift might place a critical normal structure (i.e. the spinal cord) within a high-dose volume increasing the risk of major toxicity. It will be our intention however to consider utilizing these targeting technologies in future investigations. Sachsman et al. (2014), Int J Particle Ther 698
8 Conclusion Proton therapy with concomitant capecitabine as delivered on the University of Florida Proton Therapy Institute PC01 protocol was well-tolerated with no grade 2 or greater gastrointestinal toxicities. Four of the 11 enrolled patients achieved a radiographic response allowing for attempted surgical resection. The median survival of 18.4 months and 2-year freedom from local progression rate of 64% compare favorably with previously reported treatment regimens. The lack of meaningful toxicity on this protocol suggests that protons may be a useful vehicle for treatment intensification in this setting. Such intensification might include the following: radiation therapy dose escalation; concomitant use of highly radiosensitizing chemotherapy regimens; hypofractionation of radiation therapy doses; or expansion of the radiation therapy treatment volume to cover likely sites of microscopic disease extensions. Finally, the favorable toxicity profile with this moderately aggressive regimen might suggest that protons would represent an optimal vehicle for radiation therapy delivery in the setting of neoadjuvant radiation therapy for patients with resectable or marginally resectable disease. ADDITIONAL INFORMATION AND DECLARATIONS Conflicts of Interest Disclosure: The authors have no conflicts of interest to disclose. References 1. Hazel JJ, Thirlwell MP, Huggins M, Maksymiuk A, MacFarlane JK. Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial. J Can Assoc Radiol. 1981;32: Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5- fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil an Eastern Cooperative Oncology Group study. J Clin Oncol. 1985;3: Treatment of locally unresectable carcinoma of the pancreas: comparison of combinedmodality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst. 1988;80: Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O Dwyer P, Haller D, Catalano P, Cella D, Benson AB, 3rd. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27: Loehrer PJ, Sr., Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR, Benson AB, 3rd. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29: Hammel P, Huguet F, Van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouche O, Shannon J, André T, Mineur L, Chibaudel B, Bonnetain F, Louvet C. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. J Clin Oncol. 2013;S31:LBA4003. Sachsman et al. (2014), Int J Particle Ther 699
9 7. Hsiung-Stripp DC, McDonough J, Masters HM, Levin WP, Hahn SM, Jones HA, Metz JM. Comparative treatment planning between proton and X-ray therapy in pancreatic cancer. Med Dosim. 2001;26: Bouchard M, Amos RA, Briere TM, Beddar S, Crane CH. Dose escalation with proton or photon radiation treatment for pancreatic cancer. Radiother Oncol. 2009;92: Kozak KR, Kachnic LA, Adams J, Crowley EM, Alexander BM, Mamon HJ, Fernandez- Del Castillo C, Ryan DP, DeLaney TF, Hong TS. Dosimetric feasibility of hypofractionated proton radiotherapy for neoadjuvant pancreatic cancer treatment. Int J Radiat Oncol Biol Phys. 2007;68: Nichols RC, Jr., Huh SN, Prado KL, Yi BY, Sharma NK, Ho MW, Hoppe BS, Mendenhall NP, Li Z, Regine WF. Protons offer reduced normal-tissue exposure for patients receiving postoperative radiotherapy for resected pancreatic head cancer. Int J Radiat Oncol Biol Phys. 2012;83: Nichols RC, Jr., George TJ, Zaiden RA, Jr., Awad ZT, Asbun HJ, Huh S, Ho MW, Mendenhall NP, Morris CG, Hoppe BS. Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity. Acta Oncol. 2013;52: Chang DT, Schellenberg D, Shen J, Kim J, Goodman KA, Fisher GA, Ford JM, Desser T, Quon A, Koong AC. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009;115: Schellenberg D, Kim J, Christman-Skieller C, Chun CL, Columbo LA, Ford JM, Fisher GA, Kunz PL, Van Dam J, Quon A, Desser TS, Norton J, Hsu A, Maxim PG, Xing L, Goodman KA, Chang DT, Koong AC. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011;81: Polistina F, Costantin G, Casamassima F, Francescon P, Guglielmi R, Panizzoni G, Febbraro A, Ambrosino G. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol. 2010;17: Lee RY, Nichols RC, Jr., Huh SN, Ho MW, Li Z, Zaiden R, Awad ZT, Ahmed B, Hoppe BS. Proton therapy may allow for comprehensive elective nodal coverage for patients receiving neoadjuvant radiotherapy for localized pancreatic head cancers. J Gastrointest Oncol. 2013;4: Kelly P, Das P, Pinnix CC, Beddar S, Briere T, Pham M, Krishnan S, Delclos ME, Crane CH. Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2013;85:e Takatori K, Terashima K, Yoshida R, Horai A, Satake S, Ose T, Kitajima N, Kinoshita Y, Demizu Y, Fuwa N. Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer. J Gastroenterol. 2013;49: Terashima K, Demizu Y, Hashimoto N, Jin D, Mima M, Fujii O, Niwa Y, Takatori K, Kitajima N, Sirakawa S, Yonson K, Hishikawa Y, Abe M, Sasaki R, Sugimura K, Murakami M. A phase I/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis. Radiother Oncol. 2012; 103: Sachsman et al. (2014), Int J Particle Ther 700
10 19. Nichols RC, Jr., Hoppe BS. RE: Takatori K, Terashima K, Yoshida R, Horai A, Satake S, Ose T, Kitajima N, Kinoshita Y, Demizu Y, Fuwa N. Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer. J Gastroenterol. 2013; (E-pub only). J Gastrointest Oncol. 2013;4:E33 4. Sachsman et al. (2014), Int J Particle Ther 701
Particle therapy for pancreatic cancer
Review Article Particle therapy for pancreatic cancer R. Charles Nichols Jr The University of Florida Health Proton Therapy Institute, Jacksonville, FL, USA Correspondence to: R. Charles Nichols Jr, MD.
More informationPancreatic Cancer and Radiation Therapy
Pancreatic Cancer and Radiation Therapy Why? Is there a role for local therapy with radiation in a disease with such a high rate of distant metastases? When? Resectable Disease Is there a role for post-op
More informationRADIATION THERAPY WITH ONCE-WEEKLY GEMCITABINE IN PANCREATIC CANCER: CURRENT STATUS OF CLINICAL TRIALS
doi:10.1016/s0360-3016(03)00449-8 Int. J. Radiation Oncology Biol. Phys., Vol. 56, No. 4, Supplement, pp. 10 15, 2003 Copyright 2003 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/03/$
More informationAlliance A Alliance SWOG ECOG/ACRIN - NRG
Preoperative chemotherapy and chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas Alliance A021501 Alliance SWOG ECOG/ACRIN - NRG Clinical
More informationA dosimetric comparison of proton and photon therapy in unresectable cancers of the head of pancreas
A dosimetric comparison of proton and photon therapy in unresectable cancers of the head of pancreas Reid F. Thompson University of Pennsylvania, Philadelphia, Pennsylvania 1914 Sonal U. Mayekar Thomas
More informationNeoadjuvant radiotherapy for pancreatic cancer: rationale and outcomes
Review Article Neoadjuvant radiotherapy for pancreatic cancer: rationale and outcomes Rohan Deraniyagala, Emily D. Tanzler The University of Florida College of Medicine Department of Radiation Oncology,
More informationThe 2010 Gastrointestinal Cancers Symposium Oral Abstract Session: Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract
The 2010 Gastrointestinal Cancers Symposium : Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract Abstract #131: Phase I study of MK 0646 (dalotuzumab), a humanized monoclonal antibody against
More informationARROCase: Borderline Resectable Pancreatic Cancer
ARROCase: Borderline Resectable Pancreatic Cancer Resident: Jordan Kharofa, MD Staff: Beth Erickson, MD 8/2012 Medical College of Wisconsin Department of Radiation Oncology Case Presentation: 60 year old
More informationCurrent and emerging radiotherapy strategies for pancreatic adenocarcinoma: stereotactic, intensity modulated and particle radiotherapy
Review Article Page 1 of 10 Current and emerging radiotherapy strategies for pancreatic adenocarcinoma: stereotactic, intensity modulated and particle radiotherapy Sweet Ping Ng, Eugene J. Koay Department
More informationIntended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with pancreatic
Intended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with pancreatic cancer Section AA Cancer Centre Referrals In the absence of metastatic
More informationStereotactic Radiotherapy for Unresectable Adenocarcinoma of the Pancreas
Stereotactic Radiotherapy for Unresectable Adenocarcinoma of the Pancreas Daniel T. Chang, MD 1, Devin Schellenberg, MD 2, John Shen, BS 1, Jeff Kim, BS 1, Karyn A. Goodman, MD 3, George A. Fisher, MD,
More informationNEOADJUVANT THERAPY IN CARCINOMA STOMACH. Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Superspeciality Hospital, Howrah
NEOADJUVANT THERAPY IN CARCINOMA STOMACH Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Superspeciality Hospital, Howrah NEOADJUVANT THERAPY?! Few believers Limited evidence Many surgeons
More informationChemoradiotherapy after gemcitabine plus erlotinib in patients with locally advanced pancreatic cancer
JBUON 2017; 22(4): 1046-1052 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Chemoradiotherapy after gemcitabine plus erlotinib in patients with
More information17. Oesophagus. Upper gastrointestinal cancer
110 17. Upper gastrointestinal cancer Oesophagus Radical treatment For patients with localised disease, the standard curative approach to treatment is either surgery + perioperative chemotherapy, surgery
More informationConcurrent Chemoradiation of Patients with Inoperable
Med. J. Cairo Univ., VoL 81, No. 2, March: 29-34, 2013 www.medicaljournalofcairouniversity.com Concurrent Chemoradiation of Patients with Inoperable Non-Metastatic Pancreatic Cancer MOHAMED S. ELZAHI,
More information8/1/2017. Clinical Indications and Applications of Realtime MRI-Guided Radiotherapy
Clinical Indications and Applications of Realtime MRI-Guided Radiotherapy Michael F Bassetti MD PhD Assistant Professor, Department of Human Oncology University of Wisconsin, Madison. Carbone Cancer Center
More informationSurgical Management of Pancreatic Cancer
I Congresso de Oncologia D Or July 5-6, 2013 Surgical Management of Pancreatic Cancer Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University School of Medicine, Baltimore, MD Estimated
More informationAdjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009
HIGHLIGHT ARTICLE - Slide Show Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009 Muhammad Wasif Saif
More informationRadiotherapy: from Planning to Delivery. D. Genovesi Istituto Radioterapia Oncologica CHIETI
Radiotherapy: from Planning to Delivery D. Genovesi Istituto Radioterapia Oncologica CHIETI www.radioterapia.unich.it Radiotherapy: from Planning to Delivery TOPICS 1. Total Dose Prescription 2. Prescription
More informationQuestions may be submitted anytime during the presentation.
Understanding Radiation Therapy and its Role in Treating Patients with Pancreatic Cancer Presented by Pancreatic Cancer Action Network www.pancan.org August 18, 2014 If you experience technical difficulty
More informationReview of Workflow NRG (RTOG) 1308: Phase III Randomized Trial Comparing Overall Survival after Photon versus Proton Chemoradiation Therapy for
Review of Workflow NRG (RTOG) 1308: Phase III Randomized Trial Comparing Overall Survival after Photon versus Proton Chemoradiation Therapy for Inoperable Stage II-IIIB NSCLC 1 Co-Chairs Study Chair: Zhongxing
More informationNCCN Guidelines for Hepatobiliary Cancers V Web teleconference on 10/24/17
Guideline Page and Request HCC-4 the American Society of Radiation Oncology (ASTRO): We recommend further clarification of the eligibility criteria for surgical resection and liver transplantation, respectively.
More informationWhere are we with radiotherapy for biliary tract cancers?
Where are we with radiotherapy for biliary tract cancers? Professor Maria A. Hawkins Associate Professor in Clinical Oncology MRC Group Leader/Honorary Consultant Clinical Oncologist CRUK MRC Oxford Institute
More informationLinac or Non-Linac Demystifying And Decoding The Physics Of SBRT/SABR
Linac or Non-Linac Demystifying And Decoding The Physics Of SBRT/SABR PhD, FAAPM, FACR, FASTRO Department of Radiation Oncology Indiana University School of Medicine Indianapolis, IN, USA Indra J. Das,
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL RECTAL CANCER GI Site Group Rectal Cancer Authors: Dr. Jennifer Knox, Dr. Mairead McNamara 1. INTRODUCTION 3 2. SCREENING AND
More informationStereotactic body radiation therapy (SBRT) for pancreatic and non-hepatobiliary gastrointestinal (GI) malignancies
J Radiat Oncol (2013) 2:381 390 DOI 10.1007/s13566-012-0027-x REVIEW Stereotactic body radiation therapy (SBRT) for pancreatic and non-hepatobiliary gastrointestinal (GI) malignancies John G. Phillips
More informationReference No: Author(s) 12/05/16. Approval date: committee. June Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Pancreatic Adenocarcinoma Dr Colin Purcell, Consultant Medical Oncologist & on behalf of the GI Oncologists Group, Cancer
More informationSurgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty
More informationSBRT in Pancreas Cancer Role of The Radiosurgery Society
SBRT in Pancreas Cancer Role of The Radiosurgery Society Anand Mahadevan MD FRCS FRCR Chairman Division of Radiation Oncology Geisinger Health System, Danville, PA, USA. Past President and Chairman: The
More informationStereotactic MR-guided adaptive radiation therapy (SMART) for locally advanced pancreatic tumors
Stereotactic MR-guided adaptive radiation therapy (SMART) for locally advanced pancreatic tumors Anna Bruynzeel, Radiation Oncologist VU University Medical Center, Amsterdam, The Netherlands Current standard
More informationNon-Hodgkin s Lymphomas Version
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Hodgkin s Lymphomas Version 2.2015 NCCN.org Continue Principles of Radiation Therapy PRINCIPLES OF RADIATION THERAPY a Treatment with
More informationClinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer
Goto et al. Radiation Oncology (2018) 13:118 https://doi.org/10.1186/s13014-018-1063-5 RESEARCH Open Access Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer
More informationReport. biology physics. Received Jul 21, 2011, and in revised form Jan 4, Accepted for publication Jan 5, 2012
International Journal of Radiation Oncology biology physics www.redjournal.org Report Radiation Therapy Oncology Group Consensus Panel Guidelines for the Delineation of the Clinical Target Volume in the
More informationSINGLE-FRACTION STEREOTACTIC BODY RADIATION THERAPY AND SEQUENTIAL GEMCITABINE FOR THE TREATMENT OF LOCALLY ADVANCED PANCREATIC CANCER
doi:10.1016/j.ijrobp.2010.05.006 Int. J. Radiation Oncology Biol. Phys., Vol. 81, No. 1, pp. 181 188, 2011 Copyright Ó 2011 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/$ see front matter
More informationProton therapy for gastrointestinal cancers
Review Article Proton therapy for gastrointestinal cancers Ted C. Ling, Joseph I. Kang, Jerry D. Slater, Gary Y. Yang Department of Radiation Medicine, Loma Linda University Medical Center, Loma Linda,
More informationThe role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans
The role of chemoradiotherapy in GE junction and gastric cancer Karin Haustermans Overview Postoperative chemoradiotherapy Preoperative chemoradiotherapy Palliative radiation Technical aspects Overview
More informationCholangiocarcinoma. GI Practice Guideline. Michael Sanatani, MD, FRCPC (Medical Oncologist) Barbara Fisher, MD, FRCPC (Radiation Oncologist)
Cholangiocarcinoma GI Practice Guideline Michael Sanatani, MD, FRCPC (Medical Oncologist) Barbara Fisher, MD, FRCPC (Radiation Oncologist) Approval Date: October 2006 This guideline is a statement of consensus
More informationPancreas Case Scenario #1
Pancreas Case Scenario #1 An 85 year old white female presented to her primary care physician with increasing abdominal pain. On 8/19 she had a CT scan of the abdomen and pelvis. This showed a 4.6 cm mass
More informationNCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) BONE (Version , 03/28/18)
BONE (Version 2.2018, 03/28/18) NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) Radiation Therapy Specialized techniques such as intensity-modulated RT (IMRT); particle beam RT with protons, carbon ions,
More informationStereotactic radiotherapy of pancreatic cancer: techniques and results
Page 1 of 6 Hepatobiliary Stereotactic radiotherapy of pancreatic cancer: techniques and results F Deodato 1, G Macchia 1 *, S Cilla 2, A Pomo 1, L Caravatta 3, F Cellini 4, A Ciabattoni 5, GC Mattiucci
More informationDouglas B. Evans, MD 1, Ben George, MD 2, and Susan Tsai, MD, MHS 1
Ann Surg Oncol (2015) 22:3409 3413 DOI 10.1245/s10434-015-4649-2 EDITORIAL PANCREATIC TUMORS Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced-Definitions of Increasing
More informationAytul OZGEN 1, *, Mutlu HAYRAN 2 and Fatih KAHRAMAN 3 INTRODUCTION
Journal of Radiation Research, 2012, 53, 916 922 doi: 10.1093/jrr/rrs056 Advance Access Publication 21 August 2012 Mean esophageal radiation dose is predictive of the grade of acute esophagitis in lung
More informationPancreatic Cancer. BIOLOGY: Not well defined (genetic and enviromental factors) CLINICAL PRESENTATION: Abd pain, jaundice, weight loss.
EloreMed Editor: Le Wang, MD, PhD Date of Update: 2/6/2018 UpToDate: Liposomal irinotecan (Onivyde) plus FU/LV is now approved for gemcitabine-refractory metastatic pancreatic cancer and recommended by
More informationA phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008
A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 NCT02432365 Chyong-Huey Lai, MD On behalf of Principal investigator
More informationGI Tumor Board 3/8/2018. Case #1 IDEA. Case #1 Question #1 What is the next step in management?
GI Tumor Board Edward Kim George Poultsides Naseem Esteghamat Kenzo Hirose May Cho Alan Venook Arta Monjazeb Margaret Tempero George Fisher Andrew Ko Daniel Chang Thomas Semrad Sisi Haraldsdottir Case
More informationRadiotherapy for liver cancer
Received: 7 November 2015 Accepted: 10 March 2016 DOI: 10.1002/jgf2.19 REVIEW ARTICLE Radiotherapy for liver cancer Nobuyoshi Fukumitsu MD Toshiyuki Okumura MD Hideyuki Sakurai MD Proton Medical Research
More informationFirst, how does radiation work?
Hello, I am Prajnan Das, Faculty Member in the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center. We are going to talk today about some of the basic principles regarding
More informationPancreatic Adenocarcinoma: Everything You Need to Know From Cross-Sectional Imaging to Treatment
Pancreatic Adenocarcinoma: Everything You Need to Know From Cross-Sectional Imaging to Treatment Andrew W. Bowman, MD PhD Assistant Professor of Radiology Mayo Clinic Florida SCBT-MR Annual Meeting Nashville,
More informationOverview. What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013
What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013 Overview Staging and Workup Resectable Disease Surgery Adjuvant therapy Locally
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationPotential systematic uncertainties in IGRT when FBCT reference images are used for pancreatic tumors
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 16, NUMBER 3, 2015 Potential systematic uncertainties in IGRT when FBCT reference images are used for pancreatic tumors Ahmad Amoush, May Abdel-Wahab,
More informationProtocol of Radiotherapy for Small Cell Lung Cancer
107 年 12 月修訂 Protocol of Radiotherapy for Small Cell Lung Cancer Indication of radiotherapy Limited stage: AJCC (8th edition) stage I-III (T any, N any, M0) that can be safely treated with definitive RT
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationRadiation Therapy for Liver Malignancies
Outline Radiation Therapy for Liver Malignancies Albert J. Chang, M.D., Ph.D. Department of Radiation Oncology, UCSF March 23, 2014 Rationale for developing liver directed therapies Liver directed therapies
More informationOriginal Date: April 2016 Page 1 of 7 FOR CMS (MEDICARE) MEMBERS ONLY
National Imaging Associates, Inc. Clinical guidelines STEREOTACTIC RADIATION THERAPY: STEREO RADIOSURGERY (SRS) AND STEREOTACTIC BODY RADIATION THERAPY (SBRT) CPT4 Codes: Please refer to pages 5-6 LCD
More informationChanging paradigm in pancreatic cancer: from adjuvant to neoadjuvant chemoradiation
Original Article Changing paradigm in pancreatic cancer: from adjuvant to neoadjuvant chemoradiation Justin D. Anderson 1, Wen Wan 2, Brian J. Kaplan 3, Jennifer Myers 4, Emma C. Fields 1 1 Department
More informationProton Beam Therapy for Hepatocellular Carcinoma. Li Jiamin, MD Wanjie Proton Therapy Center
Proton Beam Therapy for Hepatocellular Carcinoma Li Jiamin, MD Wanjie Proton Therapy Center 1 1 Hepatocelluar carcinoma (HCC) is one of the most common cancers worldwide It is the eighth most common neoplasm
More informationTHE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA. TIMUR MITIN, MD, PhD
THE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA TIMUR MITIN, MD, PhD RESECTABLE DISEASE MANAGEMENT: RESECTABLE DISEASE Resection offers the only possibility of long term survival
More informationPractical implementation of MR-guided RT: pancreatic SBRT as an example site
Practical implementation of MR-guided RT: pancreatic SBRT as an example site Anna Bruynzeel, MD PhD Dept. of Radiation Oncology VU University medical center Amsterdam, The Netherlands VU University Medical
More informationIGRT Protocol Design and Informed Margins. Conflict of Interest. Outline 7/7/2017. DJ Vile, PhD. I have no conflict of interest to disclose
IGRT Protocol Design and Informed Margins DJ Vile, PhD Conflict of Interest I have no conflict of interest to disclose Outline Overview and definitions Quantification of motion Influences on margin selection
More informationThe role of Radiation Oncologist: Hi-tech treatments for liver metastases
The role of Radiation Oncologist: Hi-tech treatments for liver metastases Icro Meattini, MD Radiotherapy-Oncology Unit AOU Careggi Hospital Florence University, Italy Liver Metastases - Background The
More informationIrene Giacomelli 1, Daniele Scartoni 1, Homan Mohammadi 2, William F. Regine 3, Michael D. Chuong 4. Original Article
Original Article Does lymphocyte-to-monocyte ratio before, during, or after definitive chemoradiation for locally advanced pancreatic cancer predict for clinical outcomes? Irene Giacomelli 1, Daniele Scartoni
More information肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 Outline Current status of radiation oncology in lung cancer Focused on stage III non-small cell lung cancer Radiation
More informationCorporate Medical Policy
Corporate Medical Policy Intensity Modulated Radiation Therapy (IMRT) of Abdomen and File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_abdomen_and_pelvis
More informationJoshua Richter, Muhammad Wasif Saif. Yale University School of Medicine. New Haven, CT, USA
HIGHLIGHT ARTICLE Locally Advanced Pancreatic Adenocarcinoma: Where Are We and Where Are We Going? Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010
More informationArm A: Induction Gemcitabine 1000 mg/m 2 IV once a week for 6 weeks.
ECOG-4201 (RTOG Endorsed) ECOG 4201 Pancreas (RTOG Endorsed)-1 Protocol Status: Opened: April 10, 2003 Closed: December 15, 2005 Title: A Randomized Phase III Study of Gemcitabine in Combination with Radiation
More informationImaging in gastric cancer
Imaging in gastric cancer Gastric cancer remains a deadly disease because of late diagnosis. Adenocarcinoma represents 90% of malignant tumors. Diagnosis is based on endoscopic examination with biopsies.
More informationProton Stereotactic Radiotherapy: Clinical Overview. Brian Winey, Ph.D. Physicist, MGH Assistant Professor, HMS
Proton Stereotactic Radiotherapy: Clinical Overview Brian Winey, Ph.D. Physicist, MGH Assistant Professor, HMS Acknowledgements Radiation Oncologists and Physicists at various institutions (MGH, MDACC,
More informationStereotactic radiotherapy
Stereotactic radiotherapy Influence of patient positioning and fixation on treatment planning - clinical results Frank Zimmermann Institut für Radioonkologie Universitätsspital Basel Petersgraben 4 CH
More informationSBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience
Tozzi et al. Radiation Oncology 2013, 8:148 RESEARCH Open Access SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience Angelo Tozzi 1, Tiziana Comito 1,
More informationNIH Public Access Author Manuscript J Surg Oncol. Author manuscript; available in PMC 2012 August 01.
NIH Public Access Author Manuscript Published in final edited form as: J Surg Oncol. 2011 August 1; 104(2): 155 161. doi:10.1002/jso.21954. Neoadjuvant GTX Chemotherapy and IMRT-Based Chemoradiation for
More informationAdjuvant Therapy for Adenocarcinoma of the Pancreas: Analysis of Reported Trials and Recommendations for Future Progress
Annals of Surgical Oncology DOI: 10.1245/s10434-008-0002-3 Adjuvant Therapy for Adenocarcinoma of the Pancreas: Analysis of Reported Trials and Recommendations for Future Progress Robert A. Wolff, MD,
More informationDisclosures. Overview 8/3/2016. SRS: Cranial and Spine
SRS: Cranial and Spine Brian Winey, Ph.D. Department of Radiation Oncology Massachusetts General Hospital Harvard Medical School Disclosures Travel and research funds from Elekta Travel funds from IBA
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationUtility of 18 F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer
Utility of F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer Ngoc Ha Le 1*, Hong Son Mai 1, Van Nguyen Le 2, Quang Bieu Bui 2 1 Department
More informationInteractive Exhibit On Imaging Updates For Staging And Response Assessment In Pancreatic Cancer
Interactive Exhibit On Imaging Updates For Staging And Response Assessment In Pancreatic Cancer 1 Vinit Baliyan, MD; 1 Hamed Kordbacheh, MD; 2 Eric P Tamm, MD; 3 Theodore S Hong, MD; 4 Carlos Fernandez-Del
More informationProton Therapy: Where Are We Now and Where Are We Going? Erin Davis MSN, CRNP, ACNP BC Lead Nurse Practitioner
Proton Therapy: Where Are We Now and Where Are We Going? Erin Davis MSN, CRNP, ACNP BC Lead Nurse Practitioner Genevieve Hollis MSN, CRNP, ANP-BC, AOCN Oncology Nurse Practitioner Advanced Senior Lecturer-B
More informationErectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer. William M. Mendenhall, MD
Erectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer William M. Mendenhall, MD Meta-Analysis of Probability of Maintaining Erectile Function after Treatment of Localized Cancer Treatment
More information20. Background. Oligometastases. Oligometastases: bone (including spine) and lymph nodes
125 20. Oligometastases Background The oligometastatic state can be defined as 1 3 isolated metastatic sites, typically occurring more than six months after successful treatment of primary disease. 1 In
More informationPancreas Quizzes c. Both A and B a. Directly into the blood stream (not using ducts)
Pancreas Quizzes Quiz 1 1. The pancreas produces hormones. Which type of hormone producing organ is the pancreas? a. Endocrine b. Exocrine c. Both A and B d. Neither A or B 2. Endocrine indicates hormones
More informationPancreatic Cancer Where are we?
Pancreatic Cancer Treatment Approaches & Options Pancreatic Cancer Action Network OUMC 9/22/2016 Russell G. Postier, MD Pancreatic Cancer Where are we? Estimated 2016 data 3% of cancer cases 7% of cancer
More informationThis LCD recognizes these two distinct treatment approaches and is specific to treatment delivery:
National Imaging Associates, Inc. Clinical guidelines STEREOTACTIC RADIOSURGERY (SRS) AND STEREOTACTIC BODY RADIATION THERAPY (SBRT) CPT4 Codes: 77371, 77372, 77373 LCD ID Number: L33410 J-N FL Responsible
More informationClinical Impact of Local Progression in Pancreatic Cancer
Original Research 711 Clinical Impact of Local Progression in Pancreatic Cancer Nicholas Cardillo, BS * ; Daniel M. Seible, MD * ; Katherine E. Fero, MD; Andrew R. Bruggeman, MD; Reith R. Sarkar, BS; Alexa
More informationProton Therapy for Stage IIA-B Seminoma: A New Standard of Care for Treating Retroperitoneal Nodes
Proton Therapy for Stage IIA-B Seminoma: A New Standard of Care for Treating Retroperitoneal Nodes Richard Choo, MD 1 ; Bret Kazemba, CMD 1 ; Christopher S. Choo, MD 2 ; Scott C. Lester, MD 1 ; Thomas
More informationProton Therapy for Stage IIA-B Seminoma: A New Standard of Care for Treating Retroperitoneal Nodes
Proton Therapy for Stage IIA-B Seminoma: A New Standard of Care for Treating Retroperitoneal Nodes Richard Choo, MD 1 ; Bret Kazemba, CMD 1 ; Christopher S. Choo, MD 2 ; Scott C. Lester, MD 1 ; Thomas
More informationClinical Education A comprehensive and specific training program. carry out effective treatments from day one
Proton Therapy Clinical Education A comprehensive and specific training program carry out effective treatments from day one Forewarned is forearmed Although over 100,000 patients have been treated in proton
More informationHypofractionated radiation therapy for glioblastoma
Hypofractionated radiation therapy for glioblastoma Luis Souhami, MD, FASTRO Professor McGill University Department of Oncology, Division of Radiation Oncology Montreal Canada McGill University Health
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationPatterns of failure for stage I ampulla of Vater adenocarcinoma: a single institutional experience
Original Article Patterns of failure for stage I ampulla of Vater adenocarcinoma: a single institutional experience Jim Zhong, Manisha Palta, Christopher G. Willett, Shannon J. McCall, Frances McSherry,
More informationInnovations in Radiation Therapy, including SBRT, IMRT, and Proton Beam Therapy. Sue S. Yom, M.D., Ph.D.
Innovations in Radiation Therapy, including SBRT, IMRT, and Proton Beam Therapy Sue S. Yom, M.D., Ph.D. Disclosures Genentech: advisory, research support ImClone: research support Plexxikon: research support
More informationMight Adaptive Radiotherapy in NSCLC be feasible in clinical practice?
Might Adaptive Radiotherapy in NSCLC be feasible in clinical practice? E.Molfese, P.Matteucci, A.Iurato, L.E.Trodella, A.Sicilia, B.Floreno, S.Ramella, L.Trodella Radioterapia Oncologica, Università Campus
More informationMultiorgan Resection (Including the Pancreas) for Metastasis of Cutaneous Malignant Melanoma
MULTIMEDIA ARTICLE - Clinical Imaging Multiorgan Resection (Including the Pancreas) for Metastasis of Cutaneous Malignant Melanoma Tibor Belágyi, Péter Zsoldos, Roland Makay, Ákos Issekutz, Attila Oláh
More informationOutcomes of adjuvant radiotherapy and lymph node resection in elderly patients with pancreatic cancer treated with surgery and chemotherapy
Original Article Outcomes of adjuvant radiotherapy and lymph node resection in elderly patients with pancreatic cancer treated with surgery and chemotherapy Jessica Frakes 1, Eric A. Mellon 1, Gregory
More informationAuthor s response to reviews
Author s response to reviews Title: Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT)) - Study protocol for a national, multicentre
More informationRole of Belly Board Device in the Age of Intensity Modulated Radiotherapy for Pelvic Irradiation
Role of Belly Board Device in the Age of Intensity Modulated Radiotherapy for Pelvic Irradiation 2017 AAMD 42 nd Annual Meeting Neil C. Estabrook, MD 6 / 14 / 2017 7/5/2017 1 Conflicts of Interest None
More informationRadiotherapy What are our options and what is on the horizon. Dr Kevin So Specialist Radiation Oncologist Epworth Radiation Oncology
Radiotherapy What are our options and what is on the horizon Dr Kevin So Specialist Radiation Oncologist Epworth Radiation Oncology Outline Advances in radiotherapy technique Oligo - disease Advancements
More informationDosimetric consequences of tumor volume changes after kilovoltage cone-beam computed tomography for non-operative lung cancer during adaptive
Oncology and Translational Medicine October 2015, Vol. 1, No. 5, P195 200 DOI 10.1007/s10330-015-0054-3 ORIGINAL ARTICLE Dosimetric consequences of tumor volume changes after kilovoltage cone-beam computed
More informationChemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant CRT followed by Local Excision in ut2 Rectal Cancer
Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant CRT followed by Local Excision in ut2 Rectal Cancer Emily Chan, Qian Shi, Julio Garcia-Aguilar, Peter Cataldo, Jorge
More informationAdjuvant chemoradiotherapy for high -
43 Original Article Adjuvant chemoradiotherapy for high - risk pancreatic cancer Wang M L C, Foo K F ABSTRACT Introduction: The role of adjuvant chemoradiotherapy for resected pancreatic cancer remains
More information